<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01613586</url>
  </required_header>
  <id_info>
    <org_study_id>3652-CL-0018</org_study_id>
    <secondary_id>2011-004555-39</secondary_id>
    <nct_id>NCT01613586</nct_id>
  </id_info>
  <brief_title>A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC)</brief_title>
  <acronym>AMARANTH</acronym>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Subjects With Bladder Pain Syndrome / Interstitial Cystitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study several dose levels of ASP3652, given orally for 12 weeks, will be compared
      with placebo in the treatment of female patients with Bladder Pain Syndrome / Interstitial
      Cystitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of a screening phase, an initial 3 weeks Run-in period, a 12 weeks
      Treatment period and a 2 weeks Follow-up (FU) period.

      This study will investigate the efficacy and safety of a 12 week treatment with ASP3652 in
      female patients with Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC). Different dose
      levels of ASP3652 will be compared with placebo. ASP3652 is administered as oral tablets. The
      objectives of the study are to investigate efficacy of ASP3652 in patients with BPS/IC, to
      assess the optimal dose of ASP3652, to investigate safety and tolerability and to investigate
      pharmacokinetics and pharmacodynamics of ASP3652 in patients with BPS/IC in an out-patient
      setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Mean Daily Pain (MDP) at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Pain is assessed on an 11 point (0-10) Numerical Rating Scale (NRS), which is item 4 of the Female GenitoUrinary Pain Index (24 hours recall) (F-GUPI-24h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mean Daily Pain (MDP) at 4, 8 weeks treatment and at 2 weeks follow-up post treatment</measure>
    <time_frame>Baseline, 4 and 8 weeks treatment and 2 weeks follow-up post treatment</time_frame>
    <description>Pain is assessed on an 11 point (0-10) Numerical Rating Scale (NRS), which is item 4 of the F-GUPI-24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Female GenitoUrinary Pain Index (one week recall) (F-GUPI) Total score at 4, 8, 12 weeks treatment and at 2 weeks follow-up post treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks treatment and 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in F-GUPI Pain subscale score, Urinary subscale score, and Quality of Life Impact score at 4, 8, 12 weeks treatment and at 2 weeks follow-up post treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks treatment and at 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daily pain, assessed with item 4 of the F-GUPI-24h during Run-in, Treatment period and Follow-up post treatment</measure>
    <time_frame>Every day during the Run-in, Treatment and Follow-up post treatment periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in questionnaires at 12 weeks treatment</measure>
    <time_frame>Baseline and 12 weeks treatment</time_frame>
    <description>Bladder Pain/IC Symptom Score; O'Leary-Sant IC Symptom &amp; Problem Index; Short form McGill pain questionnaire; Female Sexual Function Index; European Quality of Life questionnaire in 5 Dimensions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Response Assessment (GRA) at 0, 4, 8 and 12 weeks treatment and at 2 weeks follow-up post treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks treatment and 2 weeks follow-up post treatment</time_frame>
    <description>GRA is assessed as change from baseline which is here start of Run-in period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Voiding parameters (urinary frequency, urinary urgency, nocturia and total urgency score ) at 4, 8, 12 weeks treatment and at 2 weeks Follow-up post treatment</measure>
    <time_frame>Baseline, 4, 8, 12 weeks treatment and 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of responders: at least 7-point decrease in F-GUPI Total score at 0, 4, 8 and 12 weeks treatment compared to baseline</measure>
    <time_frame>Baseline, 4, 8 and 12 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacokinetics at week 4, 8 and 12</measure>
    <time_frame>4, 8 and 12 weeks treatment</time_frame>
    <description>Plasma levels of ASP3652</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of pharmacodynamics at week 4, 8 and 12</measure>
    <time_frame>4, 8 and 12 weeks treatment</time_frame>
    <description>Plasma levels of anandamides</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by recording Adverse Events, Laboratory tests, electrocardiograms (ECGs) and vital signs</measure>
    <time_frame>Baseline and 12 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety as assessed by SteatoTest, adiponectin and PVR</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in questionnaires (Center for Epidemiologic Studies Depression Scale and Profile of Mood States questionnaire) at 12 weeks treatment</measure>
    <time_frame>Baseline and 12 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Withdrawal Checklist at 12 weeks treatment and at 2 weeks follow-up post treatment</measure>
    <time_frame>12 weeks treatment and 2 weeks follow-up post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">287</enrollment>
  <condition>Cystitis, Interstitial</condition>
  <condition>Urologic Diseases</condition>
  <condition>Urinary Bladder Disease</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Low dose ASP3652 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium dose ASP3652 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>High dose ASP3652 twice daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP3652</intervention_name>
    <description>Oral</description>
    <arm_group_label>Low dose ASP3652 twice daily</arm_group_label>
    <arm_group_label>Medium dose ASP3652 twice daily</arm_group_label>
    <arm_group_label>High dose ASP3652 twice daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has previously been diagnosed with BPS/IC; i.e., pelvic pain, pressure or discomfort
             perceived to be related to the urinary bladder accompanied by at least one other
             urinary symptom such as persistent urge to void or frequency, for at least 3 months
             prior to screening in absence of urinary infection or other obvious pathology or
             identifiable causes

          -  Has at enrolment a score of 4 or greater on the 11-point (0-10) NRS for average pain
             over the previous week, which is item 4 of the F-GUPI

          -  Has a mean pain score of 4.0 or greater on the 11-point (0-10) NRS for daily assessed
             pain (item 4 of F-GUPI-24H) over the last 7 days prior to randomization

          -  Is willing to comply with study requirements such as completing the questionnaires and
             diaries and attend all study visits and practicing birth control

        Exclusion Criteria:

          -  Undergone a cystoscopy with hydrodistension or undergone Botox injections in the
             bladder within 6 months prior to screening

          -  Use of pentosan polysulphate sodium within 4 weeks prior to screening

          -  Any intravesicular pharmacological treatment or other interventions for BPS/IC or
             bladder, urethral, ureteral, pelvic or peri-pelvic invasive procedure within 3 months
             prior to screening

          -  Cystitis or documented symptomatic bacterial cystitis in the last 3 months prior to
             screening

          -  Lower urinary tract malignancy, such as positive (micro) hematuria in urine sediment

          -  Neurologic disease or defect affecting bladder function or symptomatic urethral
             diverticulum or any post-partum or surgery related genital tract conditions,
             symptomatic bladder or ureteral calculi or Post Void Residual volume greater than 150
             mL

          -  Clinically significant abnormalities observed during cystoscopy or on transabdominal
             ultrasound

          -  Currently active or treated sexual transmittable diseases

          -  Substance abuse or any use of delta-9-tertrahydrocannabinol (THC) as assessed by a
             positive urine test for THC at screening

          -  Any clinically relevant concomitant disease (past or present) which would, in the
             opinion of the investigator, put the subject at risk or mask measures of efficacy

          -  Symptoms of depression, defined as a Center for Epidemiological Studies Depression
             Scale score of 27 or more

          -  Use of steroids, immunomodulators, cytochrome P4502C8 inhibitors, cannabis / THC based
             medication, opioid analgesics or antiviral / antibacterial / antifungal agents during
             the last 4 weeks before the screening

          -  Initiation, discontinuation, or variation in the dose of antidepressants,
             anticonvulsants, antimuscarinics, benzodiazepines, skeletal muscle relaxants,
             non-steroid anti-inflammatory drugs, non opioid analgesics, homeopathic medication and
             herbal therapies during the last 4 weeks before the screening. Subjects should
             continue these medications at that same stable dose throughout the study

          -  Clinically relevant abnormal urine or blood safety laboratory values or active hepatic
             and/or biliary disease (AST or ALT should not be &gt;2 times the upper limit of normal,
             total bilirubin should not be &gt;1.5 times the upper limit of normal)

          -  Participated in any clinical study or has been treated with any investigational drug
             or device within 84 days or the period stipulated by local regulations, whichever is
             longer, prior to the screening
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site: 5101</name>
      <address>
        <city>Antwerp</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5103</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5202</name>
      <address>
        <city>Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5203</name>
      <address>
        <city>Kromeriz</city>
        <zip>767 55</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5206</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5209</name>
      <address>
        <city>Plzen</city>
        <zip>301 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5210</name>
      <address>
        <city>Sternberk</city>
        <zip>785 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5201</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>686 68</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5303</name>
      <address>
        <city>Aarhus</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5301</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5302</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5406</name>
      <address>
        <city>Duisburg</city>
        <zip>47179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5403</name>
      <address>
        <city>Emmendingen</city>
        <zip>79312</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5409</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5402</name>
      <address>
        <city>Holzminden</city>
        <zip>37603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5410</name>
      <address>
        <city>Kirchheim</city>
        <zip>73270</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5405</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5404</name>
      <address>
        <city>Nurtingen</city>
        <zip>72622</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5414</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5602</name>
      <address>
        <city>Liepaja</city>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5601</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5603</name>
      <address>
        <city>Riga</city>
        <zip>1038</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 6304</name>
      <address>
        <city>Kaunas</city>
        <zip>50154</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 6302</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 6301</name>
      <address>
        <city>Vilnius</city>
        <zip>09108</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 6303</name>
      <address>
        <city>Vilnius</city>
        <zip>10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5706</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5703</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5701</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5702</name>
      <address>
        <city>Winterswijk</city>
        <zip>7101 BN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5704</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 LZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5807</name>
      <address>
        <city>Bialystok</city>
        <zip>15-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5806</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-094</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5811</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5801</name>
      <address>
        <city>Lodz</city>
        <zip>90-447</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5805</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5812</name>
      <address>
        <city>Poznan</city>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5802</name>
      <address>
        <city>Warsaw</city>
        <zip>00-865</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5804</name>
      <address>
        <city>Warsaw</city>
        <zip>01-432</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 5803</name>
      <address>
        <city>Warsaw</city>
        <zip>02-784</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5902</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5903</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 5901</name>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6006</name>
      <address>
        <city>Brasov</city>
        <zip>500152</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6003</name>
      <address>
        <city>Bucharest</city>
        <zip>0100-000</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6004</name>
      <address>
        <city>Bucharest</city>
        <zip>021392</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6007</name>
      <address>
        <city>Bucharest</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6002</name>
      <address>
        <city>Bucharest</city>
        <zip>042122</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6005</name>
      <address>
        <city>Iasi</city>
        <zip>700503</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6001</name>
      <address>
        <city>Targu Mures</city>
        <zip>540103</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6108</name>
      <address>
        <city>Moscow</city>
        <zip>101000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6103</name>
      <address>
        <city>Moscow</city>
        <zip>105425</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site: 6111</name>
      <address>
        <city>Moscow</city>
        <zip>115682</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6106</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6101</name>
      <address>
        <city>Moscow</city>
        <zip>127473</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6102</name>
      <address>
        <city>St.-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6202</name>
      <address>
        <city>Laguna</city>
        <state>Tenerife</state>
        <zip>38330</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6203</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6201</name>
      <address>
        <city>Barcelona</city>
        <zip>08850</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site 6204</name>
      <address>
        <city>Malaga</city>
        <zip>29009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 7, 2012</study_first_posted>
  <last_update_submitted>March 26, 2014</last_update_submitted>
  <last_update_submitted_qc>March 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Interstitial Cystitis</keyword>
  <keyword>Bladder Pain Syndrome</keyword>
  <keyword>Painful Bladder Syndrome</keyword>
  <keyword>ASP3652</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Urologic Diseases</mesh_term>
    <mesh_term>Urinary Bladder Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

